← All trials
NCT06572917
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2025
- Primary completion
- May 31, 2028
- Completion date
- Dec 31, 2030
- First posted
- Aug 27, 2024
- Last posted
- Aug 27, 2024
- Enrollment
- 500
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of British ColumbiaLead sponsor
- University of British ColumbiaSponsor investigator
- University of British ColumbiaOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.